Hudson Bay Capital Management’s Novo Nordisk NVO Stock Holding History

Hudson Bay Capital Management’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$35M	Buy	730,000 +604,962	+484%	+$26M	0.1%	156
2026 Q1	$4.6M	Sell	125,038 -404,165	-76%	-$19.2M	0.02%	536
2025 Q4	$26.9M	Buy	529,203 +274,597	+108%	+$14M	0.09%	193
2025 Q3	$14.1M	Buy	+254,606	New	+$14.9M	0.05%	286
2025 Q1	–	Sell	-642,000	Closed	-$53M	–	1425
2024 Q4	$55.2M	Buy	642,000 +522,774	+438%	+$56.5M	0.19%	113
2024 Q3	$14.2M	Buy	119,226 +33,226	+39%	+$4.43M	0.06%	221
2024 Q2	$12.3M	Buy	+86,000	New	+$11.4M	0.06%	199
2024 Q1	–	Sell	-39,300	Closed	-$4.07M	–	840
2023 Q4	$4.07M	Buy	+39,300	New	+$3.89M	0.03%	330
2023 Q1	–	Sell	-53,046	Closed	-$3.59M	–	950
2022 Q4	$3.59M	Sell	53,046 -6,954	-12%	-$408K	0.04%	455
2022 Q3	$2.99M	Buy	+60,000	New	+$3.21M	0.03%	607

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Hudson Bay Capital Management's NVO Position: Q2 2026 in Review

Hudson Bay Capital Management increased its Novo Nordisk (NVO) stake by 484% in Q2 2026, buying an estimated $26M and bringing the position to 730,000 shares worth $35M. The position accounts for 0.1% of the portfolio, ranked #156.

Hudson Bay Capital Management first reported a position in NVO in Q3 2022 and has held it in 10 quarters since. The position peaked at $55.2M in Q4 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Hudson Bay Capital Management held 730,000 shares of Novo Nordisk worth $35M as of Q2 2026.
Hudson Bay Capital Management bought 604,962 Novo Nordisk shares in Q2 2026, an estimated $26M.
Novo Nordisk made up 0.1% of Hudson Bay Capital Management's portfolio in Q2 2026, its #156 holding.
Hudson Bay Capital Management first reported a position in Novo Nordisk in Q3 2022 and has held it in 10 quarters since.
Hudson Bay Capital Management's Novo Nordisk position peaked at $55.2M in Q4 2024.
1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.